SEC Filings
Xeris Biopharma Adds Ex-Viatris Emerging Markets Chief Menassie Taddese To Its Board
The drugmaker expanded its board from eight to nine seats and put the new director on its Audit Committee.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
The drugmaker expanded its board from eight to nine seats and put the new director on its Audit Committee.
Earnings
The lease-to-own lender received about 2.59 million shares up front, with final settlement expected by the end of the first quarter of 2027.
Deals
The all-stock deal still awaits China's regulator, and the companies will make a new U.S. antitrust filing because the current clearance is expiring.
Deals
Each Lumentum share converts into 4.500 Marvell shares, and Lumentum gets three seats on Marvell's board once the merger closes.
SEC Filings
A new board committee will oversee manufacturing as Fluence searches for permanent leaders and sets fiscal 2026 results for November 23.
SEC Filings
The chip-measurement company will put three top executives on stage in New York, then take questions from the room.
SEC Filings
The offering would bring AAR's pro forma long-term debt to $3,003.2 million once its pending MRO Holdings deal closes.
Earnings
Lower taxes and a smaller share count helped lift Marriott's third-quarter diluted EPS to $3.04 from $2.67.
SEC Filings
The pre-revenue nuclear fuel developer ended September with $236.7 million in cash and a DOE program seat that points toward a pilot factory.
SEC Filings
The company reaffirmed 2026 revenue guidance of $325 million to $345 million and reported about $355 million in cash.
Earnings
Tempus AI cut its third-quarter net loss, but unrealized stock gains did much of the work while operations lost $56.9 million.
Earnings
The chip foundry targets a $1.1 billion annualized run rate in silicon photonics alone in the fourth quarter, its CEO said.